{
    "clinical_study": {
        "@rank": "23290", 
        "arm_group": {
            "arm_group_label": "gemcitabine", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "assess the efficacy and safety of gemcitabine in the maintenance treatment of advanced\n      non-small cell lung cancer"
        }, 
        "brief_title": "The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer", 
        "condition": "THE Efficacy and Safety of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        18~75 years Patients who were diagnosed by the histologic, cytologic diagnosis of IIIb-IV\n        non-small cell lung cancer patients who have acceptted combination chemotherapy based on\n        platinum 4 course,SD OR PR,the CR patients should accept 6 course of combination\n        chemotherapy.\n\n        3~8 weeks after patients complete first line chemotherapy(include radiotherapy) Ecog0-2\n        Expected life time longer than 3 monthes\n\n        Normal laboratory values:\n\n          -  leucocyte \u2265 4\u00d7109/L\n\n          -  neutrophil \u2265 1.5\u00d7109/L\n\n          -  platelet \u2265 100\u00d7109/L\n\n          -  Hemoglobin \u2265 10g/L\n\n          -  ALT and\n\n          -  AST \u2264 2.5\u00d7ULN (\u2264 5\u00d7ULN if liver metastasis) Signed written informed consent\n\n        Exclusion Criteria:\n\n          -  Patients have used drugs according to protocol\n\n          -  Uncontrolled  infection of Bacterial or virus or fungal\n\n          -  Patients with other malignant tumor\n\n          -  Uncontrolled brain metastases\n\n          -  Female patients during their pregnant and lactation period, or patients without\n             contracep"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01797913", 
            "org_study_id": "GEM-CJH"
        }, 
        "intervention": {
            "arm_group_label": "gemcitabine", 
            "description": "gemcitabine\uff0c1000mg/m2\uff0civgtt\uff0cDAY1&DAY8", 
            "intervention_name": "gemcitabine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Gemcitabine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 21, 2013", 
        "location": {
            "contact": {
                "email": "changjianhua@163.com", 
                "last_name": "Chang jian hua, MD,PHD", 
                "phone": "13916619284"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Cancer hospital Fudan University"
            }, 
            "investigator": {
                "last_name": "chang jian hua, MD,PHD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer", 
        "overall_contact": {
            "email": "changjianhua@163.com", 
            "last_name": "chang jian hua, MD,PHD", 
            "phone": "13916619284"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "PFS", 
            "safety_issue": "No", 
            "time_frame": "from the first cycle of treatment (day one) to two month after the last cycle"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01797913"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Chang Jian Hua", 
            "investigator_title": "Vice director of department of chemotherapy", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2008", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}